- Crimson Tide has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

The contract value is worth about €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients.

This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

Story provided by